One Year Follow-up of Study 2-79-52030-207 (PRIMARYS) in Acromegalic Patients With Macroadenoma
Completed
- Conditions
- Acromegaly
- Registration Number
- NCT01471405
- Lead Sponsor
- Ipsen
- Brief Summary
This non-interventional retrospective study aims to describe the therapeutic procedures and modalities received by patients and the correlation to hormone status, during a one year follow up from completion of the 2-79-52030-207 study.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 54
Inclusion Criteria
- Completed the 2-79-52030-207 study and received 12 injections of lanreotide Autogel 120 mg, regardless of efficacy at the end of this period.
- Subject or in case of subject's death next of kin having given their written informed consent prior to collection of the data by the sponsor (if locally required)
Exclusion Criteria
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Proportion of patients maintained on medical treatment with lanreotide Autogel 1 year Proportion of patients receiving other medical treatments 1 year
- Secondary Outcome Measures
Name Time Method Proportion of patients with at least one pituitary surgery 1 year
Trial Locations
- Locations (18)
III. Interní klinika Karlova Univerzita
🇨🇿Praha 2, Czechia
CHU de Rouen
🇫🇷Bois Guillaume, France
Groupement hôspitalier est Federation d'endocrinologie.
🇫🇷Bron, France
CHU Michallon
🇫🇷Grenoble, France
Hôpital Claude Huriez
🇫🇷Lille, France
CHU Timone
🇫🇷Marseille, France
Hôpital Bicêtre
🇫🇷Paris, France
Hôpital Haut Leveque
🇫🇷Pessac, France
CHU de Reims
🇫🇷Reims, France
Hôpital Larrey
🇫🇷Toulouse, France
Scroll for more (8 remaining)III. Interní klinika Karlova Univerzita🇨🇿Praha 2, Czechia